These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23341502)
1. Genome Fusion Detection: a novel method to detect fusion genes from SNP-array data. Thieme S; Groth P Bioinformatics; 2013 Mar; 29(6):671-7. PubMed ID: 23341502 [TBL] [Abstract][Full Text] [Related]
2. Detection of recurrent rearrangement breakpoints from copy number data. Ritz A; Paris PL; Ittmann MM; Collins C; Raphael BJ BMC Bioinformatics; 2011 Apr; 12():114. PubMed ID: 21510904 [TBL] [Abstract][Full Text] [Related]
3. The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genome. Przybytkowski E; Ferrario C; Basik M BMC Med Genomics; 2011 Jan; 4():16. PubMed ID: 21272361 [TBL] [Abstract][Full Text] [Related]
4. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Liu W; Ewing CM; Chang BL; Li T; Sun J; Turner AR; Dimitrov L; Zhu Y; Sun J; Kim JW; Zheng SL; Isaacs WB; Xu J Genes Chromosomes Cancer; 2007 Nov; 46(11):972-80. PubMed ID: 17654723 [TBL] [Abstract][Full Text] [Related]
5. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440 [TBL] [Abstract][Full Text] [Related]
6. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions. Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983 [TBL] [Abstract][Full Text] [Related]
7. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139 [TBL] [Abstract][Full Text] [Related]
14. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Liu W; Chang B; Sauvageot J; Dimitrov L; Gielzak M; Li T; Yan G; Sun J; Sun J; Adams TS; Turner AR; Kim JW; Meyers DA; Zheng SL; Isaacs WB; Xu J Genes Chromosomes Cancer; 2006 Nov; 45(11):1018-32. PubMed ID: 16897747 [TBL] [Abstract][Full Text] [Related]
16. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Kalyana-Sundaram S; Shankar S; Deroo S; Iyer MK; Palanisamy N; Chinnaiyan AM; Kumar-Sinha C Neoplasia; 2012 Aug; 14(8):702-8. PubMed ID: 22952423 [TBL] [Abstract][Full Text] [Related]
17. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Winnes M; Lissbrant E; Damber JE; Stenman G Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040 [TBL] [Abstract][Full Text] [Related]
18. Characterize the difference between TMPRSS2-ERG and non-TMPRSS2-ERG fusion patients by clinical and biological characteristics in prostate cancer. Wang S; Zhang Q; Xu D; Pan Y; Lv Y; Chen X; Zuo Y; Yang L Gene; 2018 Dec; 679():186-194. PubMed ID: 30195632 [TBL] [Abstract][Full Text] [Related]
19. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092 [TBL] [Abstract][Full Text] [Related]